Top-Rated StocksTop-RatedNASDAQ:KRYS Krystal Biotech (KRYS) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free KRYS Stock Alerts $162.04 +4.79 (+3.05%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$157.92▼$164.7350-Day Range$108.01▼$180.4252-Week Range$82.09▼$189.97Volume223,159 shsAverage Volume369,484 shsMarket Capitalization$4.62 billionP/E Ratio2,025.75Dividend YieldN/APrice Target$171.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Krystal Biotech alerts: Email Address Krystal Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside5.5% Upside$171.00 Price TargetShort InterestBearish7.61% of Shares Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment0.60Based on 10 Articles This WeekInsider TradingSelling Shares$6.21 M Sold Last QuarterProj. Earnings Growth109.52%From $1.89 to $3.96 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.22 out of 5 starsMedical Sector135th out of 909 stocksBiological Products, Except Diagnostic Industry13th out of 155 stocks 2.5 Analyst's Opinion Consensus RatingKrystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKrystal Biotech has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.61% of the outstanding shares of Krystal Biotech have been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Krystal Biotech has recently decreased by 3.12%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKrystal Biotech has received a 73.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Krystal Biotech is -0.87. Previous Next 2.6 News and Social Media Coverage News SentimentKrystal Biotech has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Krystal Biotech this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for KRYS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,210,591.00 in company stock.Percentage Held by Insiders14.10% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Krystal Biotech are expected to grow by 109.52% in the coming year, from $1.89 to $3.96 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is 2,025.75, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 147.08.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is 2,025.75, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 261.58.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 5.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About Krystal Biotech Stock (NASDAQ:KRYS)Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Read More KRYS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRYS Stock News HeadlinesApril 23, 2024 | americanbankingnews.comKrystal Biotech (NASDAQ:KRYS) Given "Buy" Rating at HC WainwrightApril 22, 2024 | bizjournals.comKrystal Biotech moves to next step in clinical trialApril 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinApril 22, 2024 | globenewswire.comKrystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the LungApril 18, 2024 | msn.comCentury Real Estate raises ₹450 crore from Edelweiss to buy land and pay debtsApril 17, 2024 | americanbankingnews.comKrystal Biotech (NASDAQ:KRYS) Given Buy Rating at Stifel NicolausApril 15, 2024 | finance.yahoo.comRecent 3.8% pullback isn't enough to hurt long-term Krystal Biotech (NASDAQ:KRYS) shareholders, they're still up 437% over 5 yearsApril 12, 2024 | msn.comKarnataka 2nd PUC Result 2024 DECLARED: How to check Class 12 result at karresults.nic.in, other official websiteApril 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinApril 12, 2024 | finance.yahoo.comThe Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros PharmaceuticalsApril 4, 2024 | tmcnet.comKrystal Biotech to Present at the American Association for Cancer Research 2024 Annual MeetingApril 4, 2024 | globenewswire.comKrystal Biotech to Present at the American Association for Cancer Research 2024 Annual MeetingMarch 27, 2024 | investorplace.com3 Strong Buy Biotech Stocks to Add to Your Q2 Must-Watch ListMarch 26, 2024 | markets.businessinsider.comAttovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory BoardsMarch 16, 2024 | finance.yahoo.comKRYS Apr 2024 180.000 callMarch 16, 2024 | finance.yahoo.comKRYS Apr 2024 145.000 putMarch 16, 2024 | finance.yahoo.comKRYS Aug 2024 210.000 callMarch 15, 2024 | bizjournals.comThese are the next generation of biotech superstars in the Bay AreaMarch 14, 2024 | finance.yahoo.comKRYS Mar 2024 210.000 callMarch 14, 2024 | finance.yahoo.comKRYS May 2024 210.000 callMarch 6, 2024 | msn.comKrystal Biotech confirms cancellation from Cowen conference due to CEO sicknessMarch 4, 2024 | ca.finance.yahoo.comKRYS May 2024 200.000 putMarch 2, 2024 | finance.yahoo.comChief Accounting Officer Kathryn Romano Sells 5,000 Shares of Krystal Biotech Inc (KRYS)March 1, 2024 | benzinga.com$1000 Invested In This Stock 5 Years Ago Would Be Worth $7,400 TodayMarch 1, 2024 | fool.com2 Stocks That Could Turn $1,000 Into $2,500 in 5 YearsFebruary 28, 2024 | seekingalpha.comKrystal Biotech, Inc. (KRYS) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comKrystal Biotech, Inc. (NASDAQ:KRYS) Q4 2023 Earnings Call TranscriptSee More Headlines Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today4/23/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:KRYS CUSIPN/A CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees229Year Founded2017Price Target and Rating Average Stock Price Target$171.00 High Stock Price Target$204.00 Low Stock Price Target$118.00 Potential Upside/Downside+4.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$0.08 Trailing P/E Ratio2,038.13 Forward P/E Ratio86.26 P/E GrowthN/ANet Income$10.93 million Net MarginsN/A Pretax Margin25.44% Return on Equity-13.31% Return on Assets-12.61% Debt Debt-to-Equity RatioN/A Current Ratio17.76 Quick Ratio17.55 Sales & Book Value Annual Sales$50.70 million Price / Sales91.68 Cash FlowN/A Price / Cash FlowN/A Book Value$27.60 per share Price / Book5.91Miscellaneous Outstanding Shares28,510,000Free Float24,494,000Market Cap$4.65 billion OptionableOptionable Beta0.85 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Krish S. Krishnan M.B.A. (Age 59)M.S., Founder, Chairman, President & CEO Comp: $1.07MMs. Suma M. Krishnan (Age 59)Founder, COO, President of R&D and Director Comp: $789.92kMs. Kathryn A. Romano (Age 42)Executive VP & Chief Accounting Officer Comp: $528.87kMr. John ThomasGeneral Counsel & Corporate SecretaryMr. John KarakkalVice President of North American Sales & MarketingMs. Christine WilsonHead of U.S. Sales and MarketingMr. Josh SuskinDirector of Human Resources & OperationsDr. Hubert C. Chen M.D. (Age 55)Senior Vice President of Clinical Development Mr. Laurent GouxSenior VP & GM of EuropeMr. Ram KamineniSenior Vice President of CMC & Technical OperationsMore ExecutivesKey CompetitorsHalozyme TherapeuticsNASDAQ:HALOCRISPR TherapeuticsNASDAQ:CRSPImmunovantNASDAQ:IMVTRevolution MedicinesNASDAQ:RVMDImmunityBioNASDAQ:IBRXView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 99,101 shares on 4/18/2024Ownership: 0.556%Hennion & Walsh Asset Management Inc.Bought 1,756 shares on 4/17/2024Ownership: 0.116%Los Angeles Capital Management LLCBought 629 shares on 4/5/2024Ownership: 0.036%PNC Financial Services Group Inc.Sold 100 shares on 3/22/2024Ownership: 0.001%Vanguard Group Inc.Bought 35,632 shares on 3/11/2024Ownership: 8.610%View All Insider TransactionsView All Institutional Transactions KRYS Stock Analysis - Frequently Asked Questions Should I buy or sell Krystal Biotech stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRYS shares. View KRYS analyst ratings or view top-rated stocks. What is Krystal Biotech's stock price target for 2024? 9 brokerages have issued twelve-month target prices for Krystal Biotech's shares. Their KRYS share price targets range from $118.00 to $204.00. On average, they anticipate the company's stock price to reach $171.00 in the next year. This suggests a possible upside of 5.5% from the stock's current price. View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts. How have KRYS shares performed in 2024? Krystal Biotech's stock was trading at $124.06 on January 1st, 2024. Since then, KRYS stock has increased by 30.6% and is now trading at $162.04. View the best growth stocks for 2024 here. When is Krystal Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our KRYS earnings forecast. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) posted its quarterly earnings data on Monday, February, 26th. The company reported $0.30 earnings per share for the quarter, beating analysts' consensus estimates of ($0.52) by $0.82. The company earned $42.14 million during the quarter, compared to the consensus estimate of $27.43 million. During the same period in the previous year, the firm posted ($1.25) earnings per share. What ETFs hold Krystal Biotech's stock? ETFs with the largest weight of Krystal Biotech (NASDAQ:KRYS) stock in their portfolio include Franklin Genomic Advancements ETF (HELX), Jacob Forward ETF (JFWD), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Harbor Disruptive Innovation ETF (INNO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA). When did Krystal Biotech IPO? Krystal Biotech (KRYS) raised $30 million in an IPO on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO. Who are Krystal Biotech's major shareholders? Krystal Biotech's stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.56%), Hennion & Walsh Asset Management Inc. (0.12%) and Los Angeles Capital Management LLC (0.04%). Insiders that own company stock include Andrew C Orth, Daniel Janney, Dino A Rossi, Kathryn Romano, Krish S Krishnan and Suma Krishnan. View institutional ownership trends. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KRYS) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
